Author | Robert L. Kirkman, MD | OncLive

Author | Robert L. Kirkman, MD

Articles

Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer

June 24, 2014

Video

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.

Dr. Kirkman on the Combination of PX-866 and Docetaxel

June 27, 2012

Video

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

x